LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.06 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.36M

Average 0.23M

LBRX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

LB Pharmaceuticals Inc Common StockNASDAQ: LBRX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows 5.8% year over year

Q1 FY2026 depreciation & amortization of $82K rose 5.8% year over year. Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at +443.4% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$82K-3.5% QoQ
Last fiscal yearDec 2025
$321K+252.7% YoY
LTMMar 2026
$325.5K— YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year+252.7%——
3-year CAGR+443.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
321K USD
Year-over-year change
+252.7%
3-year CAGR
+443.4%

Depreciation & Amortization vs competitors

How LBRX compares with its peers on the latest reported figures

  • LBRX's LTM Mar 2026 depreciation & amortization of $325.5K is the 8th highest of the 10 companies compared; the peer median is $605K.
  • Over three fiscal years its annual growth of +443.4% compares with a peer median of +18.6%.
LBRX Competitors Peer median
Depreciation & Amortization for LBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNLIDenali Therapeutics Inc.LTM Jun 2026$13.14M +17.5%+12.6%364.7%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$9.07M -35.4%+79.7%0.8%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1M +7.4%+307.8%5.0%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$631K -13.8%——
ANROAlto Neuroscience, Inc.LTM Mar 2026$605K +5.0%+24.6%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$574K -20.3%+0.2%—
GHRSGH Research PLCLTM Mar 2026$350K +12.5%+92.4%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$325.5K —+443.4%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$59K -90.6%-29.5%—
NERVMinerva Neurosciences, Inc.LTM Jun 2026$2.72K -71.9%-13.9%—
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding LBRX) $605K-13.8%+18.6%5.0%

Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development1.35M7.85M51.17M16.74M
Selling, General & Admin1.46M3.53M13.66M13.66M
Operating Expenses2.81M11.38M64.83M30.4M
Depreciation & Amortization2K4K91K321K
EBITDA(12.19M)(1.45M)(63.01M)(24.88M)
EBITDA Margin————
Operating Income(2.81M)(11.38M)(64.83M)(30.4M)
Operating Margin————
Interest Income73K811K1.72M3.92M
Interest Expense2.15M4.83M00
Other Income / Expenses(11.54M)5.1M1.73M5.2M
Income Before Tax(14.35M)(6.27M)(63.1M)(25.2M)
Pre-Tax Margin————
Income Tax Expense1K1K1K1K
Net Income(14.35M)(6.28M)(63.1M)(25.21M)
Net Margin————
EPS (Basic)(4.05)(1.77)(17.83)(1.00)
EPS (Diluted)(4.05)(1.77)(17.83)(1.00)
Weighted Avg Shares3.54M3.54M3.54M25.3M
Weighted Avg Shares (Diluted)3.54M3.54M3.54M25.3M

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Intrinsic Alpha fair value

Locked

Current Price

$40.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.